Influenza Virus Vaccine for the 2012-2013 Season

Cumulative 2012/2013 Season Lot Release Status (Updated 2/28/2013)
Flu vaccine lots that have been released by FDA and are available for distribution by the manufacturers. For information on flu vaccine distribution schedules, please contact the manufacturers directly.

Manufacturer	Total Number of Lots Released by FDA
AFLURIA CSL Limited	37
Fluarix GlaxoSmithKline Biologicals	23
FluLaval ID Biomedical Corp. of Quebec	16
FluMist MedImmune, LLC	27
Agriflu Novartis Vaccines and Diagnostics Incorporated	3
Fluvirin Novartis Vaccines and Diagnostics Limited	48
Fluzone Sanofi Pasteur, Inc.	77
Protein Sciences Corp	4

FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Silver Spring, Maryland, on February 28, 2012, to select the influenza viruses for the composition of the influenza vaccine for the 2012-2013 U.S. influenza season. During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2011-2012 vaccines, and the availability of candidate strains and reagents.

The committee recommended that the trivalent formulation influenza vaccines for the U.S. 2012-2013 influenza season contain the following:

an A/California/7/2009 (H1N1)-like virus;
an A/Victoria /361/2011 (H3N2)-like virus;
a B/Wisconsin /1/2010-like virus.

The committee also recommended the following additional B strain for inclusion with the three strains included in the trivalent formulation for quadrivalent formulation influenza vaccines: